ClinicalTrials.gg
Active, not recruitingNCT06854042Updated Aug 7, 2026

A Study of Oral E1018 in Healthy Adult Participants

A Phase 1 interventional study of E1018 and Placebo in Malaria and Healthy Participants, sponsored by Eisai Inc.. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Eisai Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 105 studies in Malaria with a site in United States — 9 open to participants now, 10 under way, none of them phase 3. Malaria · United States.

Planned enrollment
64th of 89
32 · median 45
Started
2025
with 2 others
Phase 1
62 of 105
1 open now
Registered
102nd of 105
by date

Among the 105 studies in Malaria with a site in United States, this one is the 64th largest by planned enrollment of the 89 interventional ones that give a count, is one of 3 that started in 2025, is one of 62 in phase 1, and was the 102nd registered.

Malaria

1,186 studies on the registry are indexed under Malaria; 80 are open to participants now.

Browse Malaria studies →

Open to participants now

9 of the 105 studies in Malaria with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 52 Malaria studies recruiting now, 15 (29%) set no upper age limit and 34 (65%) stop at 75 or younger; 38 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 105 studies in Malaria with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of the study is to evaluate the safety and tolerability of single ascending oral doses of E1018 in healthy adult participants and to evaluate the pharmacokinetics (PK) of E1018 in plasma and urine after single oral dose administration.

03

Conditions studied

  • Malaria
  • Healthy Participants

Browse trials for

Keywords

  • E1018
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Nonsmoking/vaping, male or female, age greater than or equal to (>=) 18 years to less than or equal (\<=) 55 years old at the time of . To be considered nonsmokers, participant must have discontinued smoking/vaping for at least 4 weeks before dosing.
  2. (BMI) >=18 and less than (\<) 30 kilogram per square meter (kg/m\^2) at Screening.

Exclusion criteria

Exclusion criteria:

  1. Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin [β-hCG] (or human chorionic gonadotropin [hCG]) test with a minimum sensitivity of 25 international units per liter (IU/L) or equivalent units of β-hCG [or hCG]). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the dose of study drug.
  2. Females of . All females will be considered to be of childbearing potential unless they are (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (that is, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing).
  3. Males who have not had a successful vasectomy (confirmed azoospermia) if their female partners are of childbearing potential and are not willing to use a highly effective method, as described below, throughout the study period and for 28 days after study drug discontinuation. If the female partner is pregnant, then males who do not agree to use latex or synthetic condoms throughout the study period and for 28 days after study drug discontinuation. No sperm donation is allowed during the study period and for 28 days after study drug discontinuation. The duration may be expanded further based on the half-life of the study drug calculated in this study.

    • A highly effective method of contraception includes any of the following:
    • total abstinence (if it is their preferred and usual lifestyle)
    • an intrauterine device or intrauterine hormone-releasing system
    • a contraceptive implant
    • an oral contraceptive (the participant's partner must have been on a stable dose of the same oral contraceptive product for at least 28 days before dosing and must agree to stay on the same dose of oral contraceptive throughout the study and for 28 days after study drug discontinuation). It is permissible that if a highly effective method of contraception is not appropriate or acceptable to the participant's partner, then the participant must agree to use a medically acceptable method of contraception, that is, double-barrier methods of contraception such as latex or synthetic condom plus diaphragm or cervical/vault cap with spermicide. The duration of contraception period may be extended based on the half-life of the study drug calculated in this study.
  4. illness that requires medical treatment within 8 weeks or a clinically significant infection that requires medical treatment within 4 weeks of dosing.
  5. Presence of concurrent febrile illness(es) at Screening or Baseline.
  6. Any history of surgery that may affect PK profiles of E1018 (example, hepatectomy, nephrectomy, digestive organ resection) or participants who have a congenital abnormality in metabolism at Screening.
  7. Any clinically abnormal symptom or organ impairment found by medical history at Screening, and physical examinations, vital signs, finding, or laboratory test results that require medical treatment at Screening or Baseline.
  8. Left bundle branch block.
  9. History of myocardial infarction, active ischemic heart disease, or clinically significant or uncontrolled arrhythmia.
  10. Known history of clinically significant drug allergy at Screening.
  11. Known history of food allergies or presently experiencing significant seasonal or perennial allergy at Screening.
  12. Known to be (HIV)-positive at Screening.
  13. Active viral hepatitis (A, B or C) as demonstrated by positive serology at Screening.
  14. History of drug or alcohol dependency or abuse, or those who have a positive urine drug test or breath alcohol test at Screening or Baseline.
  15. Currently enrolled in another clinical study or used any drug or device within 30 days or 5 half-lives (whichever is longer) preceding .
  16. Receipt of blood products within 4 weeks, or donation of blood within 8 weeks, or donation of plasma within 1 week of dosing.
  17. A history of noncompliance in any previous study or inability to comply with study conduct, as assessed by the investigator.
  18. Any other findings that the investigator feels would increase the risk of having an adverse outcome from participation in the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Cohort 1: E1018 or Placebo

    Drug: E1018 · Drug: Placebo

  • Experimental
    Cohort 2: E1018 or Placebo

    Drug: E1018 · Drug: Placebo

  • Experimental
    Cohort 3: E1018 or Placebo

    Drug: E1018 · Drug: Placebo

  • Experimental
    Cohort 4: E1018 or Placebo

    Drug: E1018 · Drug: Placebo

Interventions

  • DrugE1018

    Specified dose on specified days.

  • DrugPlacebo

    E1018 matching placebo on specified days.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-limiting Events

    Time frame: Up to Day 20

  2. Number of Participants With Adverse Events (Serious and Non-serious)

    Time frame: Up to Day 20

  3. Number of Participants With Clinically Significant Laboratory Test Results

    Time frame: Up to Day 20

  4. Number of Participants With Clinically Significant Vital Signs Values

    Time frame: Up to Day 20

  5. Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Results

    Time frame: Up to Day 20

  6. AUC(0-t): Area Under the Concentration-time Curve From Zero Time to Time of Last Quantifiable Concentration for E1018

    Time frame: Up to Day 20

  7. AUC(0-inf): Area Under the Concentration-time Curve From Zero Time Extrapolated to Infinite Time for E1018

    Time frame: Up to Day 20

  8. Cmax: Maximum Observed Concentration for E1018

    Time frame: Up to Day 20

  9. Tmax: Time at Which the Highest Drug Concentration Occurs for E1018

    Time frame: Up to Day 20

  10. t½: Terminal Elimination Phase Half-life for E1018

    Time frame: Up to Day 20

  11. CL/F: Apparent Total Clearance Following Oral Administration for E1018

    Time frame: Up to Day 20

  12. Vz/F: Apparent Volume of Distribution at Terminal Phase for E1018

    Time frame: Up to Day 20

  13. Ae: Cumulative Amount of E1018 Excreted in the Urine

    Time frame: Up to Day 6

  14. Fe: Percent (%) of Administered E1018 Dose Excreted in Urine

    Time frame: Up to Day 6

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Jul 2027, 28 months after the start.

Of 29 industry-sponsored phase 1 interventional studies under Malaria, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 18. This study's planned 28 months is above that.

Counting every sponsor, half of 93 studies reached it within 13 months; a quarter within 7 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2025
First posted
Mar 3, 2025
StartActual
Feb 26, 2025
Primary completionEst.
Jul 22, 2027
CompletionEst.
Jul 22, 2027
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06854042
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Mar 3, 2025
Start date
Feb 26, 2025
Primary completion
Jul 22, 2027 (estimated)
Completion
Jul 22, 2027 (estimated)
Last update
Aug 7, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion